CD44 and neoplasm: Tumor-incidence declined from 100% to 60% in the 104-cell group, 100% to 40% in the 5000-cell group, and 80% to 40% in the 2500-cell group with PFK158-pretreated ALDH+CD44+ SKOV3 cells (Figure 5F).